Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04310241 · ClinicalTrials.gov registry record

Visual Function Abnormalities in Strabismus and Amblyopia and Response to Therapy

A clinical trial of Amblyopia and Strabismus, sponsored by The Cleveland Clinic.

Recruiting
Registry status
150
Enrollment target
1
Study location

NCT04310241 is a study of Amblyopia and Strabismus that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 150 participants, roughly in line with the 159-participant average among 24 other Amblyopia trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04310241, a study of Amblyopia and Strabismus, is actively recruiting participants, sponsored by The Cleveland Clinic.

RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

Amblyopia and strabismus are characterized by a reduction in visual acuity, contrast sensitivity, grating acuity, vernier acuity, reading difficulties and binocular visual function deficits. Treated patients have residual visual function deficits. The purpose of the current study is to quantify various visual functions in amblyopic and strabismic participants at baseline, during and at the completion of treatment.

Conditions Studied

Interventions

  • BEHAVIORAL Patching therapy, Glasses

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2020-02-21
Est. Completion 2027-03-12

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT04310241

The ClinicalTrials.gov registry entry for NCT04310241 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 159-participant average among 24 other Amblyopia trials with a reported enrollment target. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Amblyopia appearing as the primary indexed condition, and to 1 intervention - of which Patching therapy, Glasses is the first listed.

NCT04310241 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT04310241 about?

NCT04310241 is a clinical study titled "Visual Function Abnormalities in Strabismus and Amblyopia and Response to Therapy". Amblyopia and strabismus are characterized by a reduction in visual acuity, contrast sensitivity, grating acuity, vernier acuity, reading difficulties and binocular visual function deficits. Treated patients have residual visual function deficits. The purpose of the current study is to quantify vari...

What is the current status of trial NCT04310241?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2020-02-21. Estimated completion is 2027-03-12.

What conditions does trial NCT04310241 study?

This clinical trial studies the following conditions: Amblyopia, Strabismus.

What interventions are being tested in trial NCT04310241?

The interventions under investigation include: Patching therapy, Glasses (BEHAVIORAL).

Who is sponsoring clinical trial NCT04310241?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04310241 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amblyopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.